About Concord Biotech Limited

Concord Biotech Limited is a research-driven biopharmaceutical company leading in fermentation-based Active Pharmaceutical Ingredients (APIs) and formulations. Founded in 2000, the company has evolved from a single-product operation into an integrated solutions provider spanning fermentation, semi-synthetic processes, and finished dosage forms, with four advanced manufacturing facilities in Gujarat, India. 

Concord’s core portfolio includes 30+ fermentation-based APIs and close to 100 approved formulation products across markets, backed by approvals from leading global regulators such as the US FDA, EMA/EU-GMP, and WHO, among others. The company serves more than 250 customers in 70+ countries, underscoring its global footprint and regulatory credibility . Highlights include 100+ approved formulation products across markets, 5+ ANDAs approved for products from its facilities, and 5+ molecules with 20%+ global market share, reflecting leadership in niche, complex fermentation products .

Concord is positioned as a preferred partner thanks to its end-to-end fermentation value chain—covering R&D, strain development, scale-up, and commercial manufacturing—which creates high entry barriers and supports consistent quality and compliance at scale . Therapeutic strengths include immunosuppressants, oncology, anti-infectives, and antifungals. APIs are supplied exclusively to pharmaceutical companies worldwide under a B2B model, while formulations are supplied primarily to Indian government and corporate hospitals; in the US and emerging markets across Asia, Africa, and Latin America, Concord relies on distributor collaborations .

Concord Biotech Limited’s Business Segments

• Operating divisions: The company operates two major businesses—APIs and Formulations. In FY25, APIs contributed ₹94,009 lakhs (78%) of revenue and Formulations contributed ₹26,000 lakhs (22%).
• Industries served: Concord focuses on complex, fermentation-based APIs and associated formulations across immunosuppressants, oncology, anti-infectives, and antifungals, supported by backward integration for key starting materials and robust regulatory approvals .
• Revenue by geography: In FY25, domestic sales were ₹66,183 lakhs (55%) and exports were ₹53,826 lakhs (45%), reflecting a balanced footprint across India and international markets.
• Go-to-market: APIs are B2B to pharma companies worldwide; formulations are sold in India through hospitals and via distributors in the US and other emerging markets, enabling deep reach and regulatory alignment across regions.

Concord Biotech Limited Key Management

• Sudhir Vaid, Chairman & Managing Director
• Ankur Vaid, Joint Managing Director & CEO
• Lalit Sethi, Chief Financial Officer 

Latest Updates on Concord Biotech Limited

• Regulatory milestones: Concord successfully completed inspections by South Korea’s MFDS (Dholka), SFDA (Saudi Arabia, Valthera), and received EU-GMP certification for its Valthera facility. The Dholka API site also completed a successful US FDA inspection; the company received final US FDA approval to market Teriflunomide Tablets (7 mg and 14 mg) in the United States. Concord also completed a Russian GMP inspection at the Dholka API facility .
• Capacity and launches: The injectable facility at Valthera commenced and was commissioned, expanding Concord’s formulation capabilities into sterile injectables and supporting global supply of life-saving therapies.
• Strategic investments and structure: Concord acquired 75% of Stellon Biotech Inc. in the US to manage end-to-end commercial operations, and incorporated Concord Lifegen Limited as a wholly owned subsidiary for marketing, sales, and distribution. The company also acquired 26% in Clean Max Everglades Private Limited to develop a hybrid renewable energy facility; Concord Biotech Japan KK remains a 50% joint venture.
• R&D and pipeline: FY25 R&D spend was ₹27 crore; the company registered nine DMFs, filed one ANDA and received one ANDA approval, with a pipeline of 10+ products across oncology, anti-infectives and antifungals.